UPDATE: SVB Leerink On Nektar Price Target Cut: Believes 'Likelihood Of Failure For Bempeg In Lead Indications Is Higher Than Typical For Phase 3 Trials'; Remains Positive On Partnership Terms Of Bristol-Myers Deal As Co. Retains 65% Of Profits